Drug intelligence / Profile preview

xinGengSanFang

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

xinGengSanFang is a traditional Chinese medicine (TCM) formulation administered as a granule. It is being investigated for use in the sequential intervention of patients with acute ST segment elevation myocardial infarction (STEMI). The precise herbal composition, mechanism of action, and pharmacological targets are not specified in available sources. Its use aligns with TCM principles for cardiovascular support, but detailed molecular mechanisms or active ingredients have not been disclosed in public clinical trial records[1][2].

Brand names: xinGengSanFang
Other names: xinGengSanFang granule

Beyond the preview

Go deeper on xinGengSanFang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xinGengSanFang.

Explore the full profile